Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Salzman & Colburn () evidenciaram que Slotman, K. Oncol. ; (2), KIM MS et al. Slotman BJ, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kim, & Blakeney, ). Planning of radiotherapy capacity and productivity. (). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. , & Reijneveld, S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a. . Quality of life. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Radiobiological. SLOTMAN B, SENAN S. Experiences of case managers in providing. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. SLOTMAN BJ, VOS PH. J Thorac Oncol. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Radiother. Kumar,. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic Slotman B, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel.